Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Connection

Daisy Alapat to Humans

This is a "connection" page, showing publications Daisy Alapat has written about Humans.

 
Connection Strength
 
 
 
0.382
 
  1. Alapat D. Cytoplasmic Immunoglobulin Vs. DNA Analysis by Flow Cytometry. Methods Mol Biol. 2018; 1792:35-45.
    View in: PubMed
    Score: 0.026
  2. Jiwani S, Bornhost J, Alapat D. Biphenotypic plasma cell myeloma: two cases of plasma cell neoplasm with a coexpression of kappa and lambda light chains. Int J Clin Exp Pathol. 2015; 8(7):8536-44.
    View in: PubMed
    Score: 0.022
  3. Alapat DV, Ramos JM, Anderson J, Post GR. The utility of B-cell receptor gene rearrangement studies in diagnosing diffuse large B-cell lymphoma with plasmacytic differentiation. Ann Clin Lab Sci. 2015; 45(1):79-82.
    View in: PubMed
    Score: 0.021
  4. Alapat D, Coviello-Malle J, Owens R, Qu P, Barlogie B, Shaughnessy JD, Lorsbach RB. Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma. Am J Clin Pathol. 2012 Jan; 137(1):93-100.
    View in: PubMed
    Score: 0.017
  5. Alapat DV, Ain KB, Sloan DA, Monaghan KG, Karabakhtsian RG. Disparity between tissue and serum calcitonin and carcinoembryonic antigen in a patient with medullary thyroid carcinoma. Endocrine. 2011 Apr; 39(2):148-52.
    View in: PubMed
    Score: 0.016
  6. Alapat DV, Chaudhry T, Ardakany-Taghavi R, Kohtz DS. Fiber-types of sarcomeric proteins expressed in cultured myogenic cells are modulated by the dose of myogenin activity. Cell Signal. 2009 Jan; 21(1):128-35.
    View in: PubMed
    Score: 0.014
  7. Bustamante MS, Pierson SK, Ren Y, Bagg A, Brandstadter JD, Srkalovic G, Mango N, Alapat D, Lechowicz MJ, Li H, Van Rhee F, Lim MS, Fajgenbaum DC. Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease. Haematologica. 2024 07 01; 109(7):2196-2206.
    View in: PubMed
    Score: 0.010
  8. Guo W, Zhan Y, Mery D, Siegel ER, Sun F, Cheng Y, Ashby TC, Zhang Z, Bailey C, Alapat DV, Peng H, Hadidi SA, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems. Blood Cancer J. 2024 02 14; 14(1):30.
    View in: PubMed
    Score: 0.010
  9. Al Hadidi S, Ababneh OE, Schinke CD, Thanendrarajan S, Bailey C, Smith R, Panozzo S, Alapat D, Cottler-Fox M, Tricot G, Shaughnessy JD, Zhan F, Sawyer J, Barlogie B, Zangari M, van Rhee F. Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up. Blood Adv. 2024 02 13; 8(3):703-707.
    View in: PubMed
    Score: 0.010
  10. Pierson SK, Lim MS, Srkalovic G, Brandstadter JD, Sarmiento Bustamante M, Shyamsundar S, Mango N, Lavery C, Austin B, Alapat D, Lechowicz MJ, Bagg A, Li H, Casper C, van Rhee F, Fajgenbaum DC. Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes. Blood Adv. 2023 11 14; 7(21):6652-6664.
    View in: PubMed
    Score: 0.010
  11. Sarmiento Bustamante M, Shyamsundar S, Coren FR, Bagg A, Srkalovic G, Alapat D, van Rhee F, Lim MS, Lechowicz MJ, Brandstadter JD, Pierson SK, Fajgenbaum DC. Ongoing symptoms following complete surgical excision in unicentric Castleman disease. Am J Hematol. 2023 11; 98(11):E334-E337.
    View in: PubMed
    Score: 0.009
  12. Mohan M, Gong Z, Ashby TC, Al Hadidi S, Thanendrarajan S, Schinke C, Alapat D, Shaughnessy JD, Zhan F, van Rhee F, Sawyer JR, Tian E, Zangari M. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma. Cancer. 2023 08 15; 129(16):2491-2498.
    View in: PubMed
    Score: 0.009
  13. Schinke C, Poos AM, Bauer M, John L, Johnson S, Deshpande S, Carrillo L, Alapat D, Rasche L, Thanendrarajan S, Zangari M, Al Hadidi S, van Rhee F, Davies F, Raab MS, Morgan G, Weinhold N. Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level. Blood Adv. 2022 11 22; 6(22):5873-5883.
    View in: PubMed
    Score: 0.009
  14. Kelley JT, Fuller LD, Lai KK, Yantiss RK, Dzedzik S, Alapat D, Mashayekhi A, Alpert L, Gonzalez RS, Owens SR, Arber DA, Lamps LW. Gastrointestinal, hepatic, and pancreatobiliary involvement by plasma cell neoplasms: clinicopathologic correlations in a retrospective cohort of 116 cases. Histopathology. 2022 Dec; 81(6):742-757.
    View in: PubMed
    Score: 0.009
  15. Fajgenbaum DC, Pierson SK, Kanhai K, Bagg A, Alapat D, Lim MS, Lechowicz MJ, Srkalovic G, Uldrick TS, van Rhee F. The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry. Br J Haematol. 2022 07; 198(2):307-316.
    View in: PubMed
    Score: 0.009
  16. Mohan M, Gundarlapalli S, Szabo A, Yarlagadda N, Kakadia S, Konda M, Jillella A, Fnu A, Ogunsesan Y, Yarlagadda L, Thalambedu N, Munawar H, Graziutti M, Al Hadidi S, Alapat D, Thanendrarajan S, Zangari M, van Rhee F, Schinke C. Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. Am J Hematol. 2022 06 01; 97(6):E195-E198.
    View in: PubMed
    Score: 0.009
  17. Mohan M, Kendrick S, Szabo A, Yarlagadda N, Atwal D, Pandey Y, Roy A, Parikh R, Lopez J, Thanendrarajan S, Schinke C, Alapat D, Sawyer J, Tian E, Tricot G, van Rhee F, Zangari M. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Adv. 2022 02 08; 6(3):808-817.
    View in: PubMed
    Score: 0.009
  18. Baker D, Bimali M, Carrillo L, Sachedina A, Alapat D, Hoque MS, Kottarathara M, Parikh R, Erra A, Mitma AA, Mathur P, Ogunsesan Y, Yarlagadda L, Gundarlapalli S, Thanendrarajan S, Zangari M, Van Rhee F, Tricot G, Schinke C. Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica. 2021 12 01; 106(12):3215-3218.
    View in: PubMed
    Score: 0.008
  19. Mohan M, Meek JC, Meek ME, Broadwater R, Alapat D, van Rhee F. Combinatorial treatment for unresectable unicentric Castleman disease. Eur J Haematol. 2021 Oct; 107(4):484-488.
    View in: PubMed
    Score: 0.008
  20. Mohan M, Szabo A, Yarlagadda N, Gundarlapalli S, Thanendrarajan S, Kendrick S, Schinke C, Alapat D, Sawyer J, Tian E, Tricot G, van Rhee F, Zangari M. Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma. Am J Hematol. 2021 09 01; 96(9):E341-E344.
    View in: PubMed
    Score: 0.008
  21. Danziger SA, McConnell M, Gockley J, Young MH, Rosenthal A, Schmitz F, Reiss DJ, Farmer P, Alapat DV, Singh A, Ashby C, Bauer M, Ren Y, Smith K, Couto SS, van Rhee F, Davies F, Zangari M, Petty N, Orlowski RZ, Dhodapkar MV, Copeland WB, Fox B, Hoering A, Fitch A, Newhall K, Barlogie B, Trotter MWB, Hershberg RM, Walker BA, Dervan AP, Ratushny AV, Morgan GJ. Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials. PLoS Med. 2020 11; 17(11):e1003323.
    View in: PubMed
    Score: 0.008
  22. Wyeth A, Gokden N, Alapat D, Zangari M, Pina-Oviedo S. Primary Plasma Cell Neoplasm of the Kidney Without Formation of a Mass and Its Renal Manifestations: An Interstitial Variant of Renal Plasmacytoma? Clin Lymphoma Myeloma Leuk. 2020 09; 20(9):e551-e555.
    View in: PubMed
    Score: 0.008
  23. Sridharan A, Schinke CD, Georgiev G, Da Silva Ferreira M, Thiruthuvanathan V, MacArthur I, Bhagat TD, Choudhary GS, Aluri S, Chen J, Pradhan K, Xia Y, Panjikaran M, Sims G, Bhagat CK, Bender R, Keeler L, Graber A, Heuck C, Fletcher FA, Alapat D, Weinhold N, Johnson SK, Wickrema A, Barlogie B, Morgan GJ, Shastri A, Steidl U, Will B, Verma A. Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. Blood Adv. 2019 12 10; 3(23):3962-3967.
    View in: PubMed
    Score: 0.007
  24. Abdallah AA, Alapat D, Kaur V, Atrash S. Outcomes of autologous stem cell transplant for cardiac AL-amyloidosis and cardiac light chain deposition disease. J Oncol Pharm Pract. 2020 Jul; 26(5):1128-1133.
    View in: PubMed
    Score: 0.007
  25. Nabel CS, Sameroff S, Shilling D, Alapat D, Ruth JR, Kawano M, Sato Y, Stone K, Spetalen S, Valdivieso F, Feldman MD, Chadburn A, Foss? A, van Rhee F, Lipkin WI, Fajgenbaum DC. Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease. PLoS One. 2019; 14(6):e0218660.
    View in: PubMed
    Score: 0.007
  26. Kaur V, Swami A, Alapat D, Abdallah AO, Motwani P, Hutchins LF, Jethava Y. Clinical characteristics, molecular profile and outcomes of myeloid sarcoma: a single institution experience over 13 years. Hematology. 2018 Jan; 23(1):17-24.
    View in: PubMed
    Score: 0.006
  27. Thanendrarajan S, Tian E, Qu P, Mathur P, Schinke C, van Rhee F, Zangari M, Rasche L, Weinhold N, Alapat D, Bellamy W, Ashby C, Mattox S, Epstein J, Yaccoby S, Barlogie B, Hoering A, Bauer M, Walker BA, Davies FE, Morgan GJ. The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica. 2017 09; 102(9):e364-e367.
    View in: PubMed
    Score: 0.006
  28. Schinke C, Hoering A, Wang H, Carlton V, Thanandrarajan S, Deshpande S, Patel P, Molnar G, Susanibar S, Mohan M, Mathur P, Radhakrishnan M, Hoque S, Jo Kamimoto J, Grazziutti M, van Rhee F, Zangari M, Insuasti-Beltran G, Alapat D, Post G, Yaccoby S, Epstein J, Rasche L, Johnson S, Moorhead M, Willis T, Barlogie B, Walker B, Weinhold N, Davies FE, Morgan GJ. The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica. 2017 08; 102(8):e313-e316.
    View in: PubMed
    Score: 0.006
  29. Jethava Y, Mitchell A, Zangari M, Waheed S, Schinke C, Thanendrarajan S, Sawyer J, Alapat D, Tian E, Stein C, Khan R, Heuck CJ, Petty N, Avery D, Steward D, Smith R, Bailey C, Epstein J, Yaccoby S, Hoering A, Crowley J, Morgan G, Barlogie B, van Rhee F. Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma. Blood Cancer J. 2016 07 29; 6(7):e453.
    View in: PubMed
    Score: 0.006
  30. Boota M, Schinke C, Ledoux S, Alapat D, Khan R, Barlogie B. CA-125 secreting IgG kappa multiple myeloma. Am J Hematol. 2016 Oct; 91(10):E457-8.
    View in: PubMed
    Score: 0.006
  31. Fulton E, Alapat D, Mabry A, Gao L, Shalin SC. CLL/SLL with initial presentation as a longstanding cutaneous plaque: a rare case. J Cutan Pathol. 2016 Aug; 43(8):717-21.
    View in: PubMed
    Score: 0.006
  32. Papanikolaou X, Rosenthal A, Dhodapkar M, Epstein J, Khan R, van Rhee F, Jethava Y, Waheed S, Zangari M, Hoering A, Crowley J, Alapat D, Davies F, Morgan G, Barlogie B. Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120). Blood Cancer J. 2016 Mar 25; 6:e410.
    View in: PubMed
    Score: 0.006
  33. Ravilla R, Joiner AK, Alapat D, Arnaoutakis K. An Unusual Case of Acute Promyelocytic Leukemia Presenting With Hypoplastic Bone Marrow and Pancytopenia. Am J Med Sci. 2016 Mar; 351(3):317-8.
    View in: PubMed
    Score: 0.006
  34. Bhutani M, Shahid Z, Schnebelen A, Alapat D, Usmani SZ. Cutaneous manifestations of multiple myeloma and other plasma cell proliferative disorders. Semin Oncol. 2016 06; 43(3):395-400.
    View in: PubMed
    Score: 0.006
  35. Papanikolaou X, Alapat D, Rosenthal A, Stein C, Epstein J, Owens R, Yaccoby S, Johnson S, Bailey C, Heuck C, Tian E, Joiner A, van Rhee F, Khan R, Zangari M, Jethava Y, Waheed S, Davies F, Morgan G, Barlogie B. The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma. Leukemia. 2015 Aug; 29(8):1713-20.
    View in: PubMed
    Score: 0.005
  36. Guru Murthy GS, Sawyer J, Alapat D, Samant R, Barlogie B. Strange bedfellows: mitotically active chronic myeloid leukemia in molecular complete remission, detected in focal lesion of myeloma. Clin Lymphoma Myeloma Leuk. 2014 Aug; 14(4):e127-9.
    View in: PubMed
    Score: 0.005
  37. Dholaria B, Alapat D, Arnaoutakis K. Primary bone marrow Hodgkin lymphoma in an HIV-negative patient. Int J Hematol. 2014 Apr; 99(4):503-7.
    View in: PubMed
    Score: 0.005
  38. Liu YC, Reddi HV, Waheed S, Alapat D, Highsmith WE, Edmondson RD, Barlogie B, van Rhee F. A compound T60A and V122I heterozygosity in the transthyretin gene causing early onset severe cardiac amyloidosis. Amyloid. 2014 Jun; 21(2):134-5.
    View in: PubMed
    Score: 0.005
  39. Katragadda L, Shahid Z, Restrepo A, Muzaffar J, Alapat D, Anaissie E. Preemptive intravenous immunoglobulin allows safe and timely administration of antineoplastic therapies in patients with multiple myeloma and parvovirus B19 disease. Transpl Infect Dis. 2013 Aug; 15(4):354-60.
    View in: PubMed
    Score: 0.005
  40. Pandey S, Post SR, Alapat DV, Smock KJ, Post GR. Prolonged prothrombin time correlates with serum monoclonal protein concentration in patients with plasma cell dyscrasia. Int J Lab Hematol. 2013 Aug; 35(4):421-7.
    View in: PubMed
    Score: 0.005
  41. Post GR, James L, Alapat D, Guillory V, Cottler-Fox M, Nakagawa M. A case of acquired dysfibrinogenemia in multiple myeloma treated with therapeutic plasma exchange. Transfus Apher Sci. 2013 Feb; 48(1):35-8.
    View in: PubMed
    Score: 0.004
  42. Dholaria B, Alapat D, Pandey T, Agarwal A. Plasmablastic lymphoma of the retroperitoneum in an HIV- and HCV-positive patient: hard to diagnose and harder to treat. Med Oncol. 2012 Dec; 29(5):3529-34.
    View in: PubMed
    Score: 0.004
  43. Hage CA, Ribes JA, Wengenack NL, Baddour LM, Assi M, McKinsey DS, Hammoud K, Alapat D, Babady NE, Parker M, Fuller D, Noor A, Davis TE, Rodgers M, Connolly PA, El Haddad B, Wheat LJ. A multicenter evaluation of tests for diagnosis of histoplasmosis. Clin Infect Dis. 2011 Sep; 53(5):448-54.
    View in: PubMed
    Score: 0.004
  44. Bierenbaum J, Alapat DV, Godinez C, Park AE, Zhao XF, Baer MR. Littoral cell angioma: a correctable cause of progressive pancytopenia in a patient with myelodysplastic syndrome. Leuk Res. 2010 Apr; 34(4):e117-9.
    View in: PubMed
    Score: 0.004
  45. Jacob T, Ascher E, Alapat D, Olevskaia Y, Hingorani A. Activation of p38MAPK signaling cascade in a VSMC injury model: role of p38MAPK inhibitors in limiting VSMC proliferation. Eur J Vasc Endovasc Surg. 2005 May; 29(5):470-8.
    View in: PubMed
    Score: 0.003
  46. Good PF, Alapat D, Hsu A, Chu C, Perl D, Wen X, Burstein DE, Kohtz DS. A role for semaphorin 3A signaling in the degeneration of hippocampal neurons during Alzheimer's disease. J Neurochem. 2004 Nov; 91(3):716-36.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.